Targeted therapies for adrenocortical carcinoma: IGF and beyond. - Wikidata - wikimedia - TriplyDB

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

http://www.wikidata.org/entity/Q34101433

about

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.A comparative proteomic study identified calreticulin and prohibitin up-regulated in adrenocortical carcinomas.Pathway Implications of Aberrant Global Methylation in Adrenocortical Cancer Current and emerging therapeutic options in adrenocortical cancer treatment.Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art.Diagnosis, treatment and outcome of adrenocortical cancer.Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas.Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells.Single timepoint models of dynamic systems.

P2860

Q33405908-1145F8B2-0D71-4D44-88EC-77C71B1A95E6 Q34431264-CFCE9959-F6AE-4F3C-A203-367DC10B083A Q34669541-E7D58784-62D2-4CCA-9A65-E3CE873EF25F Q35952358-CD7E6066-BCEF-4CE8-B121-CA6D26B253BC Q36183873-3B253423-119D-43E9-A7EA-24F0280CF247 Q36355661-BDAEC7F0-B1A1-4B2F-A6E7-8EAAD241583B Q38358503-88B6C553-7B3F-4B1D-950D-6A9B717F92FD Q39203872-40008403-22EE-46C7-8576-24D84D07677C Q41643174-0E65DAF9-A0F9-49C1-81DE-2CB03288FA3C Q41921708-A7B40B07-5E5B-42D2-83B7-0039A055C61F

P2860

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

http://www.wikidata.org/entity/Q34101433

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@ast

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@en

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@nl

type

label

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@ast

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@en

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@nl

prefLabel

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@ast

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@en

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@nl

P1433

Q34101433-66922517-2C10-4B95-A51E-A1776AFF95ED

P1476

Q34101433-BA394531-B57B-4E38-B316-3F64036E372B

P2093

Q34101433-0185C5A5-A4AF-4C89-BAA7-CD7193D82793

P2860

Q34101433-01D8B46A-8421-48A5-ADCB-398F0A8861D6

Q34101433-02D69EC3-2063-4431-99AB-7A385EF1482B

Q34101433-040F02DD-8F15-4D40-AB3B-DB94E2B0A519

Q34101433-07642468-8691-4A93-9F85-DD08248820DC

Q34101433-12D0B1F8-3734-448A-80D6-D96ABE1A6BC5

Q34101433-138E14ED-F645-4B7C-8358-256CA4E41E8B

Q34101433-1AA9622E-8952-4669-943E-4BFDF7351075

Q34101433-1DEEE650-FEC1-4140-A6D8-CDFB464FD998

Q34101433-25E59E57-8E5F-4E8C-9462-8654DFC3EAEF

Q34101433-2907C0FE-0ABB-4854-B281-048EE5E56EAF

P2888

Q34101433-C6361D34-A19E-46EF-B3BF-12B370E3B9C4

P304

Q34101433-E45A36BA-4D9F-4CD5-A911-32101E035F09

P31

Q34101433-4B1FE03E-FB04-4441-945D-0D4C12F9012A

P356

Q34101433-7E87B46C-923F-4948-B5C4-4ED9080CAA8D

P433

Q34101433-995AC287-5C92-410D-A3F0-EE4C78FEBD2C

P478

Q34101433-646D4A4D-1A58-423E-B80F-C303EC13A8C8

P50

Q34101433-23D1296A-FF49-48AA-932C-EC41F3B77635

Q34101433-9EB4AD92-FEF7-408E-AE5D-192F16DC559C

P577

Q34101433-2C6F1785-70DD-4EFD-9EE9-63DBE4354EC0

P6179

Q34101433-C8432C97-FCA1-4150-9A37-43D79051633A

P698

Q34101433-3A106B34-3135-4B5F-B6DA-8F4E8E80781E

P356

S12672-011-0090-6

P1433

Hormones and Cancer

P1476

Targeted therapies for adrenocortical carcinoma: IGF and beyond.

@en

P2093

Michael J Demeure

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Mutation and methylation analysis of TP53 in adrenal carcinogenesis.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer

Metastasis suppressor genes at the interface between the environment and tumor cell growth

Wnt signalling in stem cells and cancer

Fibroblast growth factor signalling: from development to cancer

Insulin and insulin-like growth factor signalling in neoplasia

Learning therapeutic lessons from metastasis suppressor proteins.

P2888

s12672-011-0090-6

P304

385-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12672-011-0090-6

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly J Bussey

Lawrence S Kirschner

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043081556

http://www.w3.org/2001/XMLSchema#string

P698

22170383

http://www.w3.org/2001/XMLSchema#string